News
TECH
55.02
-0.54%
-0.30
Bio-Techne Corp. Stock Advances 6.5%, Outperforms Peers
Dow Jones · 1d ago
Is There Now An Opportunity In Bio-Techne (TECH) After Recent Share Price Weakness
Simply Wall St · 2d ago
Weekly Report: what happened at TECH last week (0420-0424)?
Weekly Report · 4d ago
Bio-Techne (TECH) Valuation Check As New Three‑Portfolio Brand Structure Rolls Out
Simply Wall St · 4d ago
Notable healthcare headlines for the week: UnitedHealth, Eli Lilly, and Organon in focus
Seeking Alpha · 5d ago
Bio-Techne Corp. Stock Sheds 10.9%, Underperforms Peers
Dow Jones · 04/23 20:34
Bio-Techne Corp. stock underperforms Thursday when compared to competitors
MarketWatch · 04/23 20:30
Bio-Techne Down Over 10%, on Pace for Largest Percent Decrease Since February 2009 -- Data Talk
Dow Jones · 04/23 16:05
Weekly Report: what happened at TECH last week (0413-0417)?
Weekly Report · 04/20 09:40
1 S&P 500 Stock to Own for Decades and 2 We Question
Barchart · 04/20 04:52
Assessing Bio-Techne (TECH) Valuation After Its New Portfolio Brand Architecture Announcement
Simply Wall St · 04/18 15:08
Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know
Barchart · 04/17 15:32
What to Expect From Bio-Techne's Q3 2026 Earnings Report
Barchart · 04/17 10:00
Bio-Techne to debut streamlined portfolio brands at AACR Annual Meeting 2026
PUBT · 04/16 12:06
Bio-Techne reorganizes brands into R&D Systems, Bio-Techne Spatial, Bio-Techne Diagnostics
PUBT · 04/16 12:03
Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity
PR Newswire · 04/16 12:00
S&P 500 jumps 2% and these 20 stocks are fueling the rally
Seeking Alpha · 04/14 16:01
Bio-Techne sets conference call to discuss fiscal third-quarter results
PUBT · 04/14 11:04
Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results
PR Newswire · 04/14 11:00
BIO-TECHNE CORP <TECH.O>: TD COWEN CUTS TARGET PRICE TO $65 FROM $80
Reuters · 04/13 10:57
More
Webull provides a variety of real-time TECH stock news. You can receive the latest news about Bio-Techne Corp through multiple platforms. This information may help you make smarter investment decisions.
About TECH
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. This segment also manufactures and sells fully automated multiomic spatial biology instrumentation and advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.